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flow pattern and left ventricular geometry; 3) the
different geometries in low flow–low EF aortic ste-
nosis compared with normal flow are explained by
clinical factors, whereas low flow–normal EF aortic
stenosis has a strong independent relationship with
concentric remodeling; and 4) concentric remodeling
patients have lower flow and estimated plasma vol-
ume than those with other geometries. These findings
suggest a potential pathophysiological role for vol-
ume underload, rather than increased peripheral
impedance, in the development of low flow–normal
EF severe aortic stenosis.
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Ventricular Response to Dobutamine
Stress CMR Is a Predictor for Outcome
in Fontan Patients
The Fontan operation is used to treat patients
with a functional univentricular heart (1). Long-
term complications include circulatory failure,
thromboembolic events, arrhythmias, and death (1,2).
Cardiovascular magnetic resonance (CMR) using
exercise or pharmacological stress might detect early
dysfunction (3). Our aim was to evaluate the value of
dobutamine-stress CMR to predict adverse outcome
in patients with a Fontan circulation.
In earlier multicenter prospective studies, we
obtained results of low-dose (7.5 mg/kg/min)
FIGURE 1 Flow Type Stratified by Left Ventricular Geometry
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There were significant differences in geometric patterns between the different flow
types, with overall p value <0.01 for association between flow type and geometry, and
p < 0.01 for distributions within each flow type.
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dobutamine-stress CMR, serum N-terminal pro–B-
type natriuretic peptide (NT-proBNP) and cardiopul-
monary exercise testing (4). In the current study, the
composite endpoint included events during follow-
up after baseline CMR: cardiac death or
reintervention, protein-losing enteropathy, and
hospitalization or cardioversion/ablation for
arrhythmias.
Time-to-event analyses (Kaplan-Meier method)
and Cox proportional hazard regression analyses
were performed to determine the predictive value for
the endpoint. A p value <0.05 was required for the
parameter to remain in the multivariable model.
Ventricular volumes were analyzed according to
common practice and were indexed for body surface
area (4). Changes in CMR parameters during stress
were calculated as follows: parameter change ¼
parameterstress  parameterrest.
Ninety-two patients were included, median age at
stress CMR 11.5 (interquartile range [IQR]: 9.8 to 15.3)
years, median time after Fontan completion 8.0 (IQR:
6.9 to 11.3) years. Thirty-one patients had a dominant
right ventricle, 56 had a dominant left ventricle, and
in 5 the dominant ventricle was undefined. The intra-
atrial tunnel Fontan technique was used in 45, an
extracardiac conduit in 42, and an atriopulmonary
connection in 5 patients.
During dobutamine-stress, end-diastolic volume
index (85  21 vs. 73  21 ml/m2; p < 0.001) and end-
systolic volume index (39  16 vs. 26  13 ml/m2;
p < 0.001) decreased and ejection fraction increased
(55  10 vs. 65  10%; p < 0.001).
Twenty-three patients developed an event, a me-
dian 3.1 (IQR: 1.5 to 5.7) years after baseline CMR.
These events were death (n ¼ 1), cardiac reoperations
(n ¼ 7), out-of-hospital cardiac arrest (n ¼ 1), hospi-
talization/ablation for arrhythmias (n ¼ 7), pacemaker
implantation (n ¼ 5), extracardiac conduit–conduit
stenting (n ¼ 1), and coiling collaterals (n ¼ 1).
Protein-losing enteropathy was not noted.
Age at baseline CMR was similar for the event and
nonevent groups. There was no significant difference
in the presence of moderate to severe atrioventricular
valve regurgitation, present in 30% of the event
group versus 29% of the nonevent group, p ¼ 0.895.
There was no significant difference in peak VO2 (event
group: 34.4 [IQR: 24.8 to 39.4] ml/min/kg; p ¼ 0.66;
n ¼ 72), predicted VO2 peak (event group: 77.5% [IQR:
57.7 to 88.3]; p ¼ 0.14; n ¼ 72), or NT-proBNP (event
group: 13.7 [IQR: 8.2 to 47.8] pmol/l; p ¼ 0.18; n ¼ 83)
at baseline for the event versus the nonevent group.
Patients who developed an event had a lower in-
crease in ejection fraction during stress (functional
reserve [FR]) and a higher ventricular wall mass,
compared with the nonevent group (FR: 6  7 vs.
11  6%; p ¼ 0.002, mass 73  23 vs. 57  16 g/m2;
p < 0.001). We found no relation between right
ventricle/left ventricle dominance or moderate and
severe atrioventricular valve regurgitation and stress
response.
In Figure 1, the event-free survival for the different
quartiles of FR is shown. The event-free survival was
better for the patients in the highest quartile of FR
($14%) (log rank: 0.024). In the lowest,
intermediate, and highest quartiles, respectively 10,
11, and 2 patients developed an event.
In univariable analysis age at CMR and Fontan,
right ventricle morphology, (log transformed) NT-
proBNP, peak VO2, end-diastolic volume, end-
systolic volume, stroke volume, ejection fraction,
and moderate and severe atrioventricular valve
regurgitation were not found to be predictive for
the composite study endpoint. In multivariable
analyses with the significant predictors from the
univariable analysis, FR (hazard ratio [HR]: 0.86%;
95% confidence interval [CI]: 0.79 to 0.93; p <
0.001) and ventricular mass (HR: 1.04 g/m2; 95% CI:
1.02 to 1.07; p ¼ 0.001) were predictive for the
FIGURE 1 Kaplan-Meier Curve for Event-Free Survival for Functional Reserve
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Kaplan-Meier curve for event-free survival for functional reserve (FR). CMR ¼ cardiac
magnetic resonance imaging.
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study endpoint. There was no significant correla-
tion (r ¼ –0.069; p ¼ 0.510) between ventricular
mass and FR.
In this study we have demonstrated, using a com-
posite endpoint derived of common outcomes in
Fontan patients, that patients with a Fontan circula-
tion with a good ventricular response to dobutamine
stress have a lower risk of developing cardiac events
during follow-up. The relation between stress CMR
parameters and hard outcome measures has only
been reported in congenital heart disease in adults
(3). Because none of the other previously identified
predictors (end-diastolic volume index >125 ml/m2,
peak VO2, NT-proBNP) (1,2,5) related to outcome in
our young patients, who could be considered at
relatively low risk, we think stress CMR parameters,
particularly FR, may be useful early markers for
outcome in Fontan patients.
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Comparison of [18F]-FDG and [18F]-NaF
Positron Emission Tomography on
Culprit Carotid Atherosclerosis
A Prospective Study
The application of positron emission tomography
(PET) with different radioisotopes in atherosclerosis
can detect various pathological cascades within
atheroma (1). The 2-deoxy-2-[18F]-fluoro-D-glucose
(FDG) ligand was the first radioisotope introduced in
atherosclerosis study that measures inflammation
activity (1). Recently, 18-F NaF ligand representing
calcification activity within atheroma showed
superior efficacy for detecting culprit coronary
vessel when compared with the FDG ligand (2). We
performed both FDG and NaF PET for stroke
patients with carotid stenosis to determine whether
NaF is also superior to FDG for detecting culprit
atheroma.
The study protocol was approved by the institu-
tional review board of Chung-Ang University Hospi-
tal. Twenty patients with acute ischemic stroke or
transient ischemic attack with carotid artery stenosis
>50% on brain computed tomography angiography
were prospectively enrolled after providing written
informed consent. We excluded patients with active
cancer or autoimmune disease, uncontrolled diabetes
mellitus with blood glucose more than 11 mmol/l at
admission, and renal dysfunction with estimated
glomerular filtration rate <45 ml/min/1.72 m2. The
culprit (þ) group consisted of individuals with a
culprit carotid lesion, defined as a carotid stenosis
that was ipsilateral to ischemic lesions in the absence
of another embolic source. All other individuals were
deemed to have a nonculprit carotid lesion,
composing the culprit (–) group.
When a patient was stabilized, FDG and NaF PET
imaging were performed on separate days by the
same protocol (median time after stroke: 17 days).
After fasting for 8 h, 259 to 370 MBq (7 to 10 mCi) of
FDG or NaF was injected intravenously. Approxi-
mately 60 min after the injection, PET images were
acquired at 5 min/bed for the head and 1 min/bed
from the skull base to the proximal thigh right after
computed tomography scan (120 kVp, 50 mA). The
maximum standardized uptake value at the carotid
level where the atheroma was largest was selected
and divided by standardized uptake value of aortic
blood to derive the maximum target-to-blood ratio.
Letters to the Editor J A C C : C A R D I O V A S C U L A R I M A G I N G , V O L . 1 2 , N O . 2 , 2 0 1 9
F E B R U A R Y 2 0 1 9 : 3 6 7 – 8 4
370
